Drug Therapy for Autoimmune and Inflammatory Skin Conditions
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 25 September 2026 | Viewed by 873
Editors
Interests: neuro rheumatology; reproductive rheumatology; cardio rheumatology; women’s health in rheumatology
Special Issue Information
Dear Colleagues,
Autoimmune and inflammatory skin conditions represent a heterogenous group of disorders driven by the dysregulated innate and adaptive immune system affecting the largest organ in human body. These conditions can be a skin-limited condition or occur as part of broader manifestation of systemic autoimmune process. Their spectrum ranges from rare monogenic autoinflammatory disorders to common polygenic autoimmune disease. Over the past decade, major advances in understanding immunopathogenesis have led to the development of targeted immunotherapies that have transformed treatment strategies in autoimmune and inflammatory skin conditions. Biologic agents and small-molecule-based immunotherapies have demonstrated significant improvement in disease control and patient quality of life. This Special Issue aims to highlight current and emerging drug therapies for autoimmune and inflammatory skin conditions. We welcome original research articles, real-world outcomes, clinical trials, translational studies, mechanistic investigations, case reports, or case series exploring novel therapeutic strategies for the treatment of autoimmune and inflammatory skin conditions.
Dr. Sumatha Channapatna Suresh
Dr. Galina Marder
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- autoimmune skin disease
- psoriasis
- immunotherapy
- cutaneous lupus
- dermatitis
- biologic therapies
- dermatomyositis
- translational therapeutics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
